inhibits the monomer and trimer forms of TNF, blocking soluble and transmembrane TNF-α. It is administered intravenously at a dose of 3-10mg/kg over at least two hours every two to eight weeks. The half-life of infliximab is eight to 9.5 days. Adalimumab (Humira ® ) is a recombinant human IgG 1 human monoclonal antibody that binds specifically to TNF-α, blocking soluble and transmembrane TNF-α. It is administered subcutaneously every other week at a dose of 40mg/kg. As for infliximab, the half-life of adalimumab is eight to 9.5 days. All three drugs are approved for the treatment of various rheumatic disorders in adults. Etanercept is also approved for the treatment of ankylosing spondylitis, psoriasis and JIA. The spectrum of side effects is becoming clearer after years of use.
Side Effects Injection-site Reactions
After injection of etanercept or adalimumab, reddening with swelling at the injection site may occur. Although this is harmless, it may lead to reduced compliance among patients. Cooling the skin before injection may help to control this side effect.
Autoantibody Production
Experimental reduction of TNF-α activity may lead to reduced control of autoantibody formation and increased risk of infection. Clinically, antinuclear autoantibodies are found in up to 75% of patients.
Fortunately, this leads to clinical lupus erythematosus only in rare cases. Due to its chimaeric character, infliximab can also induce antichimaeric antibodies:
7 it can lead to anaphylactic reaction 8 and formation of neutralising antibodies, as well as anti-DNA antibodies, which is why it is normally administered with methotrexate (MTX). The extent to which similar effects are seen with adalimumab is unclear at the moment.
Infection
It seems that all TNF-α-blocking agents can induce infections. In particular, they can reactivate tuberculosis, which may result in sepsis. Recently, uveitis due to tuberculosis under etanercept has also been described. 9 Therefore, before using TNF-α blockers, tuberculosis must be excluded.
Induction and Reactivation of Uveitis
Reactivation is a particular problem with etanercept, 10-12 but this drug can probably also induce uveitis for the first time, as has been shown in patients with HLA-B27-associated arthritis and JIA, and also in those with rheumatoid arthritis, a disorder that is not normally associated with uveitis. In some patients, a rechallenge has shown the definite role of etanercept in this process. Induction of uveitis has only rarely been described with infliximab and adalimumab. The anti-TNF-α antibodies bind the transmembranebound TNF of T cells, inducing apoptosis of activated lymphocytes.
Guignard et al. 13 suggest that this apoptosis effect, which is not found in etanercept, may be a reason for the different effects of the three drugs.
Induction and Reactivation of Demyelinating Diseases
There are multiple reports about induction of retrobulbar optic to change medication to achieve control of ocular inflammation compared with only one patient in the infliximab group.
Adalimumab
While the experience with adalimumab is limited in adults, there is evidence for its effect in JIA-associated uveitis, substantiated by three studies that published data on its effect in groups of 14-20 patients. Unfortunately, for paediatric uveitis there are no official criteria to define the efficiency of the drug, which was the major difference between these three studies. Our group recently reported a retrospective trial of 18 patients with anterior uveitis, 17
of whom had JIA-associated anterior uveitis. 26 All of the patients had been treated previously with at least two other immunosuppressive drugs (MTX and cyclosporine A) in addition to oral corticosteroids, with no effect. Adalimumab was effective -defined by no relapse or at least two fewer relapses compared with the pre-treatment period -in 16 patients, mildly effective in one patient and not effective in one patient. The median time to response was three weeks (range two to four weeks).
Vazquez-Cobien et al. reported on 14 patients, of whom 13 showed a decrease in ocular inflammation on adalimumab, 27 defined as "sustained decrease in anterior chamber cell count over two visits three months apart". The median time to response was six weeks (range two to 12 weeks). All children had previously received at least one immunosuppressive drug that had been ineffective in treating uveitis. This study used weekly dosing instead of the standard treatment of every other week.
Recently, Tynjälä et al. 28 reported on 20 children, 18 of whom had been treated with at least one other immunosuppressive and 95% of whom had previously been on infliximab. The mean duration of adalimumab therapy was 18.7 months. Of the 20 patients, seven (35%) showed improved activity and one (5%) showed worsening activity, and in 12 patients (60%) no change was observed in the activity of uveitis. Those with improved activity were younger and had shorter disease duration. Inactive disease in this study was defined as 0 cells in the anterior chamber.
These reports, all resulting from highly selected, previously adequately treated patients from tertiary care centres, show very promising results for the use of adalimumab, since the side effectssuch as injection-site reactions and the formation of neutralising antibodies -tend to be less frequent. The difference in the improvement rate seems to be dependent on the different outcome measurements. In our study we used the reduction of recurrences, defined as continuing increase of cells in the anterior chamber for some days. We strongly believe that a cell count of 0.5 -and probably even 1+ -in CAU children is still a very good situation; this is in contrast to some other types of uveitis, which were the basis of the Standardization of Uveitis Nomenclature (SUN) criteria. 29 In this regard the SUN criteria need some revision: response criteria for CAU should be defined depending on the underlying uveitis.
Summary and Conclusions
In the 'steroid' era, there was general agreement among experts that achieving 0 cells in the anterior chamber of CAU children was generally too difficult and that the prognosis in terms of the visual outcome might not be better. In the current era, new studies are needed regarding the response criteria and the final end-point of an effective treatment.
Because of the half-lives of the TNF-α-blocking drugs, we strongly recommend controlling children at different time-points in the interval of application: the most reliable day for estimating the number of cells in the anterior chamber is just before re-administration of the drug. • For how long do the drugs have to be used?
• What is the result of combining these drugs with immunosuppressive drugs in terms of increasing effectiveness and reducing antibody production?
• How should ineffective treatment be handled: changing regimen, reducing the treatment interval or adding other immunosuppressives?
• Why do some children with chronic uveitis respond very well to etanercept while others do not?
• Why do TNF-α blockers become ineffective after a certain period of time (without autoantibody production), and why is it effective
Effectiveness of Adalimumab in the Therapy of Paediatric Uveitis Adalimumab in Juvenile Idiopathic Arthritis-associated Chronic Anterior Uveitis Tynjälä P, et al., Rheumatology (Oxford), 2008; 47:339-44 .
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